AnaptysBio, Inc. (ANAB) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
AnaptysBio, Inc. (ANAB) posted $234.60M in revenue for fiscal 2025 (up 157.0% year over year), with a net loss of $13.23M, and has compounded revenue about 25.6%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on AnaptysBio, Inc.
AnaptysBio, Inc. has grown revenue from $16.68M to $234.60M over the last 10 fiscal years, compounding about 25.6% a year. The most recent year was up 157%, so growth is actually accelerating.
Net margin sits at -5.6%, up 153.5 points year over year.
At today's valuation the market is pricing in roughly 26.8% annual free-cash-flow growth. The one thing worth a second look in the filings is currently unprofitable.
Synthesised from AnaptysBio, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
AnaptysBio, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.68M | $10.00M | $5.00M | $8.00M | $75.00M | $63.17M | $10.29M | $17.16M | $91.28M | $234.60M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-4.26M | $-30.07M | $-61.66M | $-97.34M | $-19.93M | $-57.80M | $-128.72M | $-163.62M | $-145.23M | $-13.23M |
| Net margin | -25.5% | -300.7% | -1233.1% | -1216.7% | -26.6% | -91.5% | -1251.3% | -953.7% | -159.1% | -5.6% |
Source: AnaptysBio, Inc. SEC filings (10-K). 11 years of history available in the interactive view.
AnaptysBio, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -5.6%).
What growth is priced into ANAB stock?
At today's market cap of $1.57B, AnaptysBio, Inc. is priced for free-cash-flow growth of about 26.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $19.61M from the FY ending 2025-12-31). For comparison, revenue 25.6%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 11 years of AnaptysBio, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ANAB in your portfolio →
AnaptysBio, Inc. financial history by metric
About AnaptysBio, Inc.
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
AnaptysBio, Inc. — frequently asked questions
What is AnaptysBio, Inc.'s revenue?
AnaptysBio, Inc. (ANAB) reported revenue of $234.60M for fiscal year 2025, up 157.0% from the prior year, according to its SEC filings.
Is AnaptysBio, Inc. profitable?
No — ANAB reported a net loss of $-13.23M in fiscal 2025.
What is ANAB's P/E ratio?
AnaptysBio, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is AnaptysBio, Inc. growing?
ANAB's revenue grew at roughly 25.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does AnaptysBio, Inc. have?
As of fiscal year 2025, ANAB carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is AnaptysBio, Inc.'s market cap?
AnaptysBio, Inc. (ANAB) has a market capitalization of about $1.57B, based on the latest data in our nightly-refreshed cache.
When does AnaptysBio, Inc.'s fiscal year end?
ANAB's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into ANAB stock?
At today's market cap of $1.57B, AnaptysBio, Inc. is priced for free-cash-flow growth of about 26.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $19.61M from the FY ending 2025-12-31). For comparison, revenue 25.6%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from AnaptysBio, Inc.'s official SEC filings (10-K and 10-Q), covering 11 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.